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Actinobacillus pleuropneumoniae is the etiologic agent of porcine contagious
pleuropneumonia, a significant disease that causes serious economic losses to
the swine industry worldwide. Persistent infections caused by bacterial biofilms are
recalcitrant to treat because of the particular drug resistance of biofilm-dwelling cells.
TolC, a key component of multidrug efflux pumps, are responsible for multidrug
resistance (MDR) in many Gram-negative bacteria. In this study, we identified two TolC-
like proteins, TolC1 and TolC2, in A. pleuropneumoniae. Deletion of tolC1, but not tolC2,
caused a significant reduction in biofilm formation, as well as increased drug sensitivity
of both planktonic and biofilm cells. The genetic-complementation of the tolC1 mutation
restored the competent biofilm and drug resistance. Besides, biofilm formation was
inhibited and drug sensitivity was increased by the addition of phenylalanine-arginine
beta-naphthylamide (PAβN), a well-known efflux pump inhibitor (EPI), suggesting a role
for EPI in antibacterial strategies toward drug tolerance of A. pleuropneumoniae. Taken
together, TolC1 is required for biofilm formation and is a part of the MDR machinery
of both planktonic and biofilm cells, which could supplement therapeutic strategies for
resistant bacteria and biofilm-related infections of A. pleuropneumoniae clinical isolate
SC1516.
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INTRODUCTION
Actinobacillus pleuropneumoniae, a facultative anaerobic Gram-negative coccobacillus belonging
to the family Pasteurellaceae, is the etiological agent of porcine pleuropneumonia characterized
by serious fibrino-hemorrhagic necrotizing pneumonia and fibrinous pleurisy (Bosse et al.,
2002). This disease often manifests as severe outbreaks, causing significant economic losses in
porcine industry worldwide. Even though considerable progress has been made in unmasking
the pathogenesis of A. pleuropneumoniae, much remains to be studied (Chiers et al., 2010).
In particular, little is known regarding how A. pleuropneumoniae confers resistance against
bactericidal substances for survival and spread within the host.
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Bacteria often live in compact microbial communities
enclosed in a self-produced matrix called biofilms that attach to
biotic or abiotic surfaces (Van Acker et al., 2014). Biofilms protect
bacterial cells by decreasing their susceptibility to bactericides
and the host immune system, which makes biofilm formation the
basis of many persistent infections in humans and animals (Mah,
2012). Bacteria growing in biofilms are often largely resistant to
antimicrobial agents and the mechanisms of drug resistance of
biofilm cells are not fully understood. In A. pleuropneumoniae,
biofilm formation is prevalent among field isolates (Kaplan and
Mulks, 2005). In addition, antimicrobial treatments were still
necessary to prevent the spread of A. pleuropneumoniae, for
that the currently available vaccination provides only partial
protection and limited impact on morbidity (Bossé et al., 2015).
Various antibiotic resistance patterns have been reported in
A. pleuropneumoniae, which become a problem for the control
of porcine pleuropneumonia outbreaks (Wang et al., 2010;
Kucerova et al., 2011; Pridmore et al., 2011). Therefore, antibiotic
resistance and biofilm formation present big challenges for
antimicrobial therapies in A. pleuropneumoniae.
In A. pleuropneumoniae, several resistance genes or plasmids
were identified (Wang et al., 2010; Archambault et al., 2012),
while drug eﬄux pumps were poorly understood. In most Gram-
negative bacteria, eﬄux pumps that actively extrude multiple
structural classes of antibacterials out of the cells, play a key
role in multidrug resistance (MDR) phenotypes (Blair et al.,
2014). Eﬄux pumps were also suggested to be involved in
antimicrobial resistance of biofilms and in the ability to form
biofilms in several bacterial species: Escherichia coli, Klebsiella
pneumoniae, and Salmonella typhimurium (Kvist et al., 2008; Van
Acker and Coenye, 2016). Little is known about the contribution
of eﬄux pumps to antibiotic resistance and biofilm formation in
A. pleuropneumoniae.
Classically, eﬄux transporters can be divided into five families:
ABC (ATP-binding cassette), RND (resistance nodulation
division), MFS (major facilitator superfamily), SMR (small
MDR), and MATE (multidrug and toxic compound extrusion)
families or superfamilies (Li et al., 2015). Usually, the first three
families of transporters function in the form of tripartite eﬄux
pumps, which involve a periplasmic adaptor protein and an
outer membrane eﬄux protein (OEP), which is usually TolC or
a TolC-like homolog (Koronakis et al., 2004; Du et al., 2015).
Clinically, the most significant eﬄux pumps in Gram-negative
bacteria are members of the RND family (Morita et al., 2012; Anes
et al., 2015), among which AcrAB-TolC of E. coli is best studied
(Zgurskaya et al., 2011). With a channel-tunnel structure, TolC
functions as an exit duct of AcrAB-TolC system for diverse types
of substances when recruited by the substrate-engaged inner
membrane complexes, conferring intrinsic resistance to a large
variety of antimicrobial agents such as antibiotics, detergents
as well as host-derived bile salts and antimicrobial peptides
(Piddock, 2006; Horiyama et al., 2010). In fact, bacteria may have
a number of different transporters, but only a limited number
of OEPs, which makes TolC family proteins a key component of
eﬄux pumps (Koronakis et al., 2004).
In this study, we identified two TolC-like proteins, encoded
by the genes APL_RS01335 (tolC1) and APL_RS04400 (tolC2),
respectively, in A. pleuropneumoniae genome. Analyses of the
mutants revealed that tolC1, but not tolC2, was involved in
MDR of planktonic and biofilm cells. In addition, tolC1 was
also shown to be required for biofilm formation. Chemical
inhibition of eﬄux pumps by Phe-Arg-β-naphthylamide (PAβN)
not only increased the drug susceptibility, but also repressed
biofilm formation and eradicated mature biofilms, indicating
a potential application of eﬄux pump inhibitors (EPIs) as
adjunctive therapies in antibacterial and antibiofilm strategies in
A. pleuropneumoniae.
MATERIALS AND METHODS
Strains and Growth Conditions
Bacterial strains, plasmids and primers used in this study are
listed in Tables 1 and 2. Wild-type A. pleuropneumoniae strain
SC1516, isolated from an outbreak on a farm in Sichuan,
China in 2014, was used in the current study. SC1516 and
derivatives were grown in Tryptic Soy Broth (TSB, Difco
Laboratories, Detroit, MI, USA) or on Tryptic Soy agar (TSA,
Difco Laboratories, Detroit, MI, USA) supplemented with 5%
bovine serum (Invitrogen, USA) and 0.01% β-nicotinamide
adenine dinucleotide (NAD). Where necessary, the media
were supplemented with 50 µg/ml kanamycin or 5 µg/ml
chloramphenicol. E. coli strains were grown on Luria-Bertani
(LB, Difco Laboratories, Detroit, MI, USA) agar or in broth.
When required, the media were supplemented with 25 µg/ml
chloramphenicol and 1 mM diaminopimelic acid (Sigma-
Aldrich, St. Louis, MO, USA). Unless otherwise stated, all strains
were grown at 37◦C.
Bioinformatic Analysis
The NCBI BLAST package was used to perform homology
searches, and DNAMAN 4.0 was employed for similarity
and identity analyses. A neighbor-joining tree containing 34
sequences from members of the TolC family was constructed
using Mega 5.0 software program, and viewed through iTOL1.
Construction of tolC1 and tolC2 Mutants
and Genetically Complemented Strains
in A. pleuropneumoniae
For creation of the tolC1 mutant, a DNA fragment of 842-
bp obtained from tolC1 (from 24 to 865 bp) was joined with
the chloramphenicol acetyl transferase gene (cat) from pMC-
Express (Bosse et al., 2009) by overlap PCR. The resulting PCR
product was cloned into a pMD19-T vector (Takara, Japan)
to give pLCT. pLCT was electroporated into SC1516 and the
transformants were selected on TSA supplemented with 5 µg/ml
chloramphenicol, 5% bovine serum and 0.01% NAD, resulting in
the tolC1 mutant.
To delete the full length of tolC2 gene, the 1000-bp
upstream and downstream regions flanking the tolC2 gene
were PCR-amplified from chromosomal DNA of SC1516,
1http://itol.embl.de/
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and fused using overlap extension PCR. The resulting PCR
product was cloned into the suicide vector pEMOC2 to
generate plasmid pEMOC2-1tolC2. The resulting plasmid
pEMOC2-1tolC2 was conjugated into SC1516 using the
E. coli strain β2155 (Xie et al., 2013). After two homologous
recombination steps, the tolC2 mutant was identified by
PCR.
For genetic complementation, the entire coding
regions of tolC1 and tolC2 together with their
promoters were cloned into the shuttle vector pLS88 to
generate plasmids pLStolC1 and pLStolC2, respectively.
The resulting plasmids were electroporated into the
corresponding mutant strains and the transformants
were selected on TSA with 5% bovine serum and
TABLE 1 | Bacterial strains and plasmids used in this study.
Strain or plasmid Characteristicsa Source or reference
Strains
Actinobacillus pleuropneumoniae
SC1516 Serovar 7 clinical isolate Laboratory collection
tolC1::cat tolC1 insertion mutant of SC1516 This study
1tolC2 tolC2 deletion mutant of SC1516 This study
tolC1::cat tolC1+ The complemented strain of tolC1::cat containing the tolC1 gene This study
1tolC2/tolC2 The complemented strain of 1tolC2 containing the tolC2 gene This study
Escherichia coli
DH5α General cloning host strain TAKARA
BL21 (DE3) General expression host strain TAKARA
β2155 thrB1004 pro thi hsdS lacZ1M15 (F
′
lacZ1M15 lacIq traD36 proA+ proB+) 1dap::erm (Ermr) Baltes et al., 2003
Plasmids
pMD19-T Ampr, E. coli cloning vector TAKARA
pET39b Kanr, E. coli expression vector Novagen
pEMOC2 Transconjugation vector based on pBluescript SK with mobRP4, a polycloning site, Cmr, and
transcriptional fusion of the omlA promoter with the sacB gene
Baltes et al., 2003
pEMOC2-1tolC2 1000 bp left and 1000 bp right homologous fragment of tolC2 cloned into pEMOC2 This study
pMC-express Cmr, expression vector of A. pleuropneumoniae Bosse et al., 2009
pLCT pMD19-T carrying the 24–865 bp of tolC1 gene fragment and an cat cassette This study
pLS88 Broad-host-range shuttle vector from Haemophilus ducreyi; Strr Kanr Willson et al., 1989
pLStolC1 Kanr, tolC1 gene with its native promoter in pLS88 This study
pLStolC2 Kanr, tolC2 gene with its native promoter in pLS88 This study
aErmr, erythromycin resistance; Ampr, ampicillin resistance; Kanr, kanamycin resistance; Cmr, chloramphenicol resistance; Strr, streptomycin resistance; cat,
chloramphenicol acetyltransferase.
TABLE 2 | Primers used in this study.
Primer name Sequence (5′→3′)a Description
tolC1-pET39b-F AGTACTGACGGTTCGCTTGAACAAG (ScaI) Primers for tolC1 gene cloning and expression
tolC1-pET39b-R CTCGAGTTATCTTCTATATTTACCC (XhoI)
tolC2-pET39b-F AGTACTTTGCAGTCCGATATTGAATTACC (ScaI) Primers for tolC2 gene cloning and expression
tolC2-pET39b-R CTCGAGTTACCAACCGCCCCCAATCGAT(XhoI)
tolC2-L-F AGCGGGCCCGTCAAAAACGGTTCCGTTGC (ApaI) Cloning the 1000 bp upstream of tolC2 into pEMOC2
tolC2-L-R AGTTGTTCCTATATTCTTAT
tolC2-R-F ATAAGAATATAGGAACAACTAATCTATACATTTCGAACGG Cloning the 1000 bp downstream of tolC2 into pEMOC2
tolC2-R-R ATTTGCGGCCGCTAAATATTCCGCATAAACAC (NotI)
tolC1-F AACACTCTCCGTTGTACTTG Primers used for cloning the 24–865 bp of tolC1 gene
tolC1-R AATAAGGGTAACTATTGCCGCATCCGGGCGATTTGCGATTG
cat-F CGGCAATAGTTACCCTTATT Primers used for amplification of the chloramphenicol resistance gene
cat-R TTCAACTAACGGGGCAGGTT
tolC1-pls88-F CGGAATTCGCGTTTAAAACAAGCTTCTC (EcoRI) Primers used for amplification of tolC1 gene and its native promoter
tolC1-pls88-R CATGCCATGGAGCGCAATACTATCTTCTAT (NcoI)
tolC2-pls88-F CGGAATTCCACAAAGTCTAACCCAACTT (EcoRI) Primers used for amplification of tolC2 gene and its native promoter
tolC2-pls88-R CATGCCATGGTTATTGCTCCGTTCGAAATG (NcoI)
aRestriction sites are underlined. The 20-bp extensions required for overlap PCR are indicated in bold text.
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0.01% NAD containing kanamycin or kanamycin and
chloramphenicol.
Expression of Recombinant TolC1 and
TolC2 and Generation of Rabbit Antisera
Recombinant proteins of TolC1 and TolC2 were generated using
an E. coli expression system. Briefly, PCR fragments containing
tolC1 or tolC2 genes minus their signal peptide sequences were
amplified from genomic DNA of SC1516 using primers tolC1-
pET39b-F/R and tolC2-pET39b-F/R, respectively. The resulting
PCR products were cloned into the ScaI and XhoI sites of
pET39b to form plasmid pET39b-TolC1 and pET39b-TolC2.
These recombinant plasmids were transformed into E. coli BL21
(DE3) and induced to express by the addition of 0.5 mM
isopropyl-beta-D-thiogalactopyranoside (IPTG). Recombinant
proteins were purified by Ni affinity chromatography using
Profinity IMAC Ni-Charged Resin (Bio-Rad) as described (Zhang
et al., 2016).
Rabbit immunization was carried out in strict accordance
with procedures approved by the Sichuan Agricultural
University Institutional Animal Care and Use Committee.
Antisera were generated by immunized each rabbit
subcutaneously with 0.5 mg of recombinant TolC1 and
TolC2 containing the same volume of complete Freund’s
adjuvant (Sigma) on day 0 (primary immunization). On
days 14 and 21, the rabbits were immunized subcutaneously
with 0.5 mg of recombinant proteins that were mixed with
incomplete Freund’s adjuvant (Sigma). Serum samples were
collected 1 week after the final immunization and stored at
−70◦C.
Western Blotting
Western blotting analyses were performed as described
previously (Zhang et al., 2015). Briefly, whole-cell extracts of
wild-type strain SC1516, mutants and genetically complemented
strains were separated on 12% Sodium dodecylsulfate
(SDS) – polyacrylamide gel electrophoresis (PAGE) and
electrotransferred onto nitrocellulose membranes, respectively.
After blocking in 5% skimmed milk in TBST (Tris-HCl buffered
saline containing 0.05% Tween 20) at room temperature for
30 min, the membranes were incubated with rabbit antiserum
for 3 h at room temperature. After three washes with TBST,
the membranes were hybridized with horseradish peroxidase-
conjugated goat anti-rabbit IgG antibody (Bioss, China) for
30 min at room temperature. Membranes were washed five times
with TBST and the signal was detected with the Immun-Star
Western C Kit (Bio-Rad, USA) according to the manufacturer’s
instructions.
In vitro Growth Assays
Growth of A. pleuropneumoniae SC1516 and its derivatives was
determined by transferring 1 ml overnight culture into 100 ml
of fresh TSB with 5% bovine serum and 0.01% NAD. Bacteria
cultures were incubated while shaking at 37◦C. Growth was
monitored by measuring the optical density (OD) at 600 nm
(OD600) with the SmartSpec Plus spectrophotometer (Bio-Rad).
Antibiotic Susceptibility Assays
Assays on the minimal inhibitory concentration for planktonic
cells (MIC-P) were carried out using 17 antibiotics, detergents
and dyes that were reported to be eﬄux pump substrates
(Martinez et al., 2009). The MIC-P was determined by a
broth micro-dilution assay using serial twofold dilution in TSB
with 5% bovine serum and 0.01% NAD. The microtiter plates
were incubated at 37◦C and visually scored for growth or
no growth at 24 h. All antibiotics used in this study were
obtained from Sigma-Aldrich, Co. (St. Louis, MO, USA). The
experiments were independently performed at least three times
in triplicate.
The minimal bactericidal concentrations for biofilms (MBC-
B) were determined as described (Zhang and Mah, 2008).
Overnight-grown biofilms in a 96-well microtiter plate were
exposed to serially diluted antibiotics of choice for at least 12 h.
Then, fresh TSB supplemented with 5% bovine serum and 0.01%
NAD was used to replace the antibiotic-containing medium and
incubated for additional 24 h. The viability of bacteria in biofilms
was assessed by transferring a spot of the culture onto a TSA
with 5% bovine serum and 0.01% NAD. The experiments were
independently performed at least three times in triplicate.
For co-treatments of antibiotics and PAβN, appropriate final
concentration (60 µg/ml for the MIC-P assay and 160 µg/ml for
the MBC-B assay) of PAβN (Sigma, USA) was added into the
medium containing antibiotics.
Crystal Violet Biofilm Assays
Biofilm formation assays were performed as described previously
with minor changes (Kaplan et al., 2004; Zhang et al., 2016).
Briefly, overnight cultures of SC1516 and its derivatives were
diluted 1/100 into fresh TSB with 5% bovine serum and 0.01%
NAD and incubated statically in sterile 96-well microtiter plates
(Costar 3599, Corning, NY, USA). After 12 h at 37◦C, bacterial
growth (OD600) was measured using a microplate reader (Bio-
Rad iMarkTM microplate Reader). Culture supernatant was then
removed and the wells were washed by immersing in water and
stained with 100 µl of crystal violet (0.1%, w/v) per well for
5 min at room temperature. After that, crystal violet was removed
and washed with distilled water. The bound dye was released by
adding 100 µl of acetic acid (33%, v/v) and the optical density was
measured at 595 nm using a microplate reader.
For the biofilm inhibition assays, overnight broth culture of
SC1516 was diluted (1/100) into fresh TSB with 5% bovine serum
and 0.01% NAD in the presence of PAβN (0, 20, 40, and 60µg/ml)
alone, or with subminimal inhibitory concentrations of antibiotic
(0.25 µg/ml of ceftazidime, 0.0625 µg/ml of ofloxacin, or 1 µg/ml
of gentamicin) for planktonic cells (sub-MIC-P). Control wells
were without any antibiotics or PAβN. Biofilms quantified as
described above.
For the eradication assays of established biofilms, overnight
biofilms of SC1516 in a 96-well microtiter plate were exposed
to PAβN (160 µg/ml), or subminimal-bactericidal concentration
for biofilms (sub-MBC-B) of antibiotic (1 µg/ml of ceftazidime,
1 µg/ml of ofloxacin, or 10 µg/ml of gentamicin) with or without
PAβN. Control wells were without any antibiotics or PAβN. After
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24 h of incubation, supernatants were removed and replaced with
fresh TSB with 5% bovine serum and 0.01% NAD for additional
12 h. Biofilms were stained with crystal violet and quantified as
described above. All crystal violet biofilm assays were performed
at least three times in triplicate.
Confocal Laser Scanning Microscopy
Static biofilms were grown on 20-mm2 coverglasses submerged
in 3 ml TSB with 5% bovine serum and 0.01% NAD in 6-
well microtiter plate for 12 h. The supernatants were removed
and the biofilms were exposed to 10 µg/ml of gentamicin with
or without 160 µg/ml of PAβN for additional 24 h. Then
biofilms were washed with water three times and stained with
the LIVE/DEAD@ BacLightTM Bacterial Viability Kit (catalog no.
L13152; Molecular Probes, Invitrogen, USA) or Wheat Germ
Agglutinin (WGA)–Oregon Green@ 488 (Invitrogen, Molecular
Probes, Eugene, OR, USA). Plates were incubated for 15 min
at room temperature in the dark and washed for three times
with water. Stained biofilms were examined with a Nikon
A1R confocal scanning laser microscope (CLSM). The images
were analyzed using the NIS-Elements AR software (Nikon,
Japan).
Statistical Analysis
Data were analyzed with the GraphPad Prism version 6.0
(GraphPad Software, San Diego, CA, USA). One- or two-way
analysis of variance (ANOVA) was employed to determine the
difference between more than two groups. Differences were
considered statistically significant at ∗P < 0.05.
RESULTS
A. pleuropneumoniae Encodes Two TolC
Homologs
Bioinformatic analysis showed the presence of two tolC homologs
in the genomes of all serotypes of A. pleuropneumoniae available
in NCBI. In strain SC1516, the two TolC homologs, named
TolC1 and TolC2, are encoded by tolC1 and tolC2, with GenBank
accession numbers KU705812 and KU705813, respectively.
TolC1 showed similarity to a number of bacterial TolC proteins
detected through a BLAST search against the GenBank, including
representative members from Haemophilus influenzae (HI1462;
56% identity), Klebsiella pneumoniae (CusC; 26% identity) and
E. coli (TolC; 22% identity). TolC2 showed similarity to Vibrio
cholerae VceC (30% identity), Pseudomonas aeruginosa OprM
(27% identity) and H. influenzae HI1462 (23% identity). Besides,
TolC1 and TolC2 proteins are both 464 amino acids with
99.78 and 98.98% sequence identity among different serotypes of
A. pleuropneumoniae, respectively.
Phylogenetic analysis was performed to investigate the
evolutionary relationships of A. pleuropneumoniae TolC1 and
TolC2 to other members of the TolC family. Thirty six proteins
(see Supplementary Table S1) were clustered into three different
groups (groups A, B, and C; Figure 1). Both TolC1 and TolC2
of A. pleuropneumoniae were phylogenetically clustered into the
group A that seems to be mainly involved in the multidrug eﬄux.
Construction of tolC1 and tolC2 Mutants
and Genetically Complemented Strains
in A. pleuropneumoniae
Initially, we attempted to inactivate both tolC1 and tolC2 genes by
the suicide vector pEMOC2 carrying a counter-selection system
(Xie et al., 2013). A 1tolC2 was easily obtained while multiple
attempts to delete tolC1 were unsuccessful. Therefore, tolC1 was
disrupted using plasmid pLCT as described in Section “Materials
and Methods.” Gene disruption in tolC1::cat and 1tolC2
mutants and genetic complementation in tolC1::cat tolC1+ and
1tolC2/tolC2 strains were confirmed by PCR (Supplementary
Figure S1).
To further confirm the mutations, Western blotting was
performed with rabbit antisera. We do not know how much
cloned proteins were incorporated to the membrane fraction, but
the mutation can be confirmed by reading the positive/negative
band. For TolC1, the antiserum identified a 50 kDa protein in
the wild-type strain SC1516 and in the genetically complemented
strain tolC1::cat tolC1+, but absent in the tolC1::cat strain.
Similarly, the antiserum against TolC2 detected a protein with
the expected size in both SC1516 and genetically complemented
1tolC2/tolC2, but not in 1tolC2 (Figure 2). The results were
consistent with the PCR data, confirming that both tolC1::cat and
1tolC2 have lost their ability to express corresponding proteins.
In contrast, the expression of TolC1 and TolC2 were restored in
both genetically complemented mutants.
Next, we compared the growth of the wild-type SC1516 and
its derivatives. The tolC1::cat strain showed a slight growth delay
in the log phage, but reached similar optical density in the
stationary phase (Figure 3A). Genetic complementation restored
the growth kinetics of tolC1::cat tolC1+ strain to the wild-type
level. There was no significant difference in growth kinetics
between SC1516 and1tolC2 (Figure 3B).
TolC1, but not TolC2, Is Part of the
Multidrug Resistance Machinery of
A. pleuropneumoniae
To determine the roles of TolC1 and TolC2 in MDR of planktonic
cells, MIC-P assays were carried out using a broth micro-dilution
assay. As shown in Table 3, for the tolC1::cat strain, the MICs
of novobiocin, ceftazidime, and lincomycin decreased by 256-
, 8- and 4-fold, while the MICs of nalidixic acid, kanamycin
and tetracycline decreased by twofold, respectively. Additionally,
tolC1::cat also showed enhanced susceptibility to various
fluoroquinolones. Moreover, tolC1::cat was also more susceptible
to non-antibiotic antimicrobials, including acriflavine, crystal
violet and SDS by 8-, 8-, and 4-fold, respectively. In contrast,
tolC1::cat showed similar levels of resistance to its parental
wild-type SC1516 for gentamicin, rifampin and polymyxin B,
suggesting that these compounds might not be substrates of
TolC1-dependent eﬄux systems. Resistance to the majority of
the compounds was returned back to wild-type levels in the
genetically complemented strain tolC1::cat tolC1+, confirming
that the observed antibiotic susceptibility of tolC1::cat mutant
was not caused by polarity effects. In addition, no change was
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FIGURE 1 | Location of TolC1 and TolC2 of Actinobacillus pleuropneumoniae in the TolC family phylogenetic tree. The TolC homologs can be grouped
into three major clades, named Groups A, B, and C. Group A proteins seem to be mainly involved in multidrug efflux (black), Group B proteins mainly in cation efflux
(green) and Group C proteins are multifunctional (blue). Proteins were labeled as “protein name-species name” according to details in Supplementary Table S1.
observed in sensitivity to vancomycin, suggesting that the loss
of TolC1 seemed not to perturb outer membrane integrity of
planktonic A. pleuropneumoniae negatively.
Next, we used MBC-B assays to examine if TolC1 was
involved in the antibiotic resistance of biofilm cells. The
tolC1::cat biofilm bacteria had significantly increased sensitivity
to varieties of antimicrobial agents (Table 3). In contrast,
tolC1::cat tolC1+ bacteria were as resistant as the wild-type
SC1516. In general, TolC1 conferred resistance to same classes
of antibiotics in both planktonic cells and biofilm cells, except
for gentamicin and rifampin, to which the MBC-B of tolC1::cat
mutant was both decreased by fourfold (Table 3). Interestingly,
when compared against wild-type SC1516, 1tolC2 mutant
did not show significant increase in susceptibility to any of
these aforementioned antimicrobials (Supplementary Table S2).
Collectively, these results suggested that TolC1 is involved in
multidrug eﬄux and resistance in both planktonic and biofilm
cells of A. pleuropneumoniae SC1516.
The Mutant Lacking a Functional TolC
Impairs Biofilm Formation in
A. pleuropneumoniae
Crystal violet biofilm assays were employed to examine the effect
of tolC1 mutation on biofilm formation of A. pleuropneumoniae.
Biofilm phenotypes of wild-type strain SC1516, tolC1::cat mutant
FIGURE 2 | Western blotting of TolC1 and TolC2 (A), Western blotting of
TolC1 in whole-cell lysate of A. pleuropneumoniae probed with rabbit
antiserum. Lane 1, wild-type strain SC1516; Lane 2, tolC1::cat strain; Lane
3, genetically complemented tolC1::cat tolC1+ strain. (B) Western blotting of
TolC2 in whole-cell lysate of A. pleuropneumoniae probed with rabbit
antiserum. Lane 1, wild-type strain SC1516; Lane 2, 1tolC2 strain; Lane 3,
genetically complemented 1tolC2/tolC2 strain. Target proteins are indicated
with an arrow. The bands at about 75 kDa showed a cross-reactive protein.
and the complemented strain tolC1::cat tolC1+ were compared.
The ability to form biofilms was decreased significantly in
tolC1::cat (Figure 4A). In contrast, tolC1::cat tolC1+ formed
biofilms of wild-type level. Furthermore, SC1516, tolC1::cat
and tolC1::cat tolC1+ showed similar growth kinetics in static
cultures (Supplementary Figure S2A), which showed that the
disruption of TolC1 did not cause a growth defect under the
given culture conditions. The results indicated that inactivation
of TolC1-dependent multidrug eﬄux pumps reduces the ability
of A. pleuropneumoniae to form biofilms.
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FIGURE 3 | Growth kinetics of the wild-type strain SC1516, tolC mutants and genetically complemented strains in TSB broth. (A) The tolC1 mutant
showed a reduced growth rate in the log phage, while later reached similar optical density in the stationary phase. (B) The tolC2 mutant exhibited the same growth
kinetics with the wild-type strain. Data presented here are means of triplicate experiments and error bars represent standard deviations.
PAβN Restores the Drug Susceptibility of
Planktonic and Biofilm Cells in
A. pleuropneumoniae
PAβN is a competitive inhibitor of RND eﬄux pumps (Zechini
and Versace, 2009). We examined the susceptibility of wild-
type SC1516 and tolC1::cat mutant to PAβN. The MIC of
PAβN for tolC1::cat was eightfold lower than that for SC1516
and the genetically complemented tolC1::cat tolC1+ (Table 3),
indicating that PAβN was transported in a TolC1-dependent
way in A. pleuropneumoniae. To determine the competitive
inhibitory effect of PAβN on eﬄux pumps, novobiocin was
employed as an indicator. Based on the MIC (80 µg/ml)
of PAβN for wild-type SC1516, sub-MICs of PAβN (20, 40,
and 60 µg/ml) were added for the novobiocin susceptibility
assays. At 20 µg/ml, PAβN was insufficient to block drug
eﬄux and the sensitivity to novobiocin was not affected. The
novobiocin sensitivity was significantly increased 16-fold in the
presence of 40 µg/ml of PAβN and 64-fold in the presence
of 60 µg/ml of PAβN. Therefore, 60 µg/ml of PAβN was
employed as the optimum concentration in subsequent MIC-
P assays, and 160 µg/ml (1/2 MBC-B, Table 3) in the biofilm
assays.
To determine the effect of PAβN on drug susceptibility
of A. pleuropneumoniae planktonic cells, MIC-P assays were
carried out in the presence of cocktail drugs composed of
PAβN and antibiotics. PAβN increased the susceptibility of
SC1516 to rifampin by 256-fold. Additionally, the susceptibility
to ceftazidime, ofloxacin, lincomycin, and polymyxin B
was increased by 2–4 fold. Moreover, MICs of acriflavine,
deoxycholate, crystal violet, and SDS were decreased by 2–8 fold,
while the MIC of novobiocin decreased by 64-fold (Table 3).
To assess the efficacy of PAβN on the antibiotic sensitivity
of biofilm cells, MBC-B assays were performed with PAβN in a
cocktail with novobiocin, ofloxacin, ceftazidime, nalidixic acid,
gentamicin, and rifampin, respectively. Overnight biofilm cells
showed 2–4 fold higher sensitivity to PAβN-antibiotic cocktails
than individual antibiotic alone (Table 3). Taken together, these
results indicate that PAβN efficiently inhibits multidrug eﬄux
pumps and increases the killing activity of various classes
of antibiotics against both planktonic and biofilm cells of
A. pleuropneumoniae.
PAβN Enhances the Inhibitory Effects of
Antibiotics on Bacterial Biofilm
Formation
Crystal violet staining assay was also employed to assess the
effect of PAβN on biofilm formation. The addition of PAβN
significantly reduced biofilm formation of SC1516 in a dose-
dependent manner (Figure 4B). The effective concentrations
of PAβN required were below the MIC (80 µg/ml), indicating
that PAβN performed a specific antibiofilm effect rather than
a substantial inhibition on planktonic growth (Supplementary
Figure S2B).
Because PAβN increased drug susceptibility of biofilm cells
and suppressed biofilm formation, we examined if the antibiofilm
efficacies of sub-MIC-P of antibiotics (ceftazidime, ofloxacin, or
gentamicin) could be enhanced by PAβN. Low concentration of
antibiotic alone caused no significant inhibition, and in some
cases, or even induced biofilm formation (Figure 5). Importantly,
when compared against individual antibiotics alone, addition of
PAβN significantly enhanced the ability of these antimicrobials
to inhibit biofilm formation by the wild-type strain SC1516
(Figure 5). Furthermore, cocktails of PAβN with ceftazidime
or ofloxacin were slightly more effective than PAβN alone in
inhibiting biofilm formation.
PAβN Enhances the Eradication Effects
of Antibiotics on Established Biofilms
Given its significant inhibitory effect on biofilm formation, the
cocktail PAβN-antibiotic strategy might be efficacious in the
eradication on established biofilms. Biofilm eradication assays
were performed using sub-MBC-B of ceftazidime, ofloxacin,
and gentamicin plus PAβN. As shown in Figure 6A, low
concentration of each antibiotic alone had no effect on biofilm
eradication, while the combination of each antibiotic with
PAβN diminished the mature biofilms significantly. These
results indicated that the eradication activity of sub-MBC-B of
antibiotics on biofilms was substantially enhanced by PAβN.
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To visualize the eradication of mature biofilms by cocktail
of PAβN-antibiotics, CLSM assays were performed as described
in Section “Materials and Methods.” Biofilms were stained
with SYTO-9 and propidium iodide to label live and dead
bacteria, respectively. Biofilm architectures were characterized
using a WGA fluorescent probe that specifically labeled
exopolysaccharide PGA, the key scaffolding component of
A. pleuropneumoniae biofilms (Hathroubi et al., 2016). Biofilm
eradication was determined by the relative abundance of live
cells and the content of PGA. When compared against the
untreated group, the addition of gentamicin alone did not
diminish pre-established biofilms. In contrast, a cocktail drug
composed of gentamicin with PAβN substantially eradicated
biofilms (Figures 6B,C). Both viable cells and biofilm matrix were
reduced, showing sparse bacteria colonies and scattered WGA
fluorescent spots. Taken together, these data demonstrate that
PAβN enhances the ability of various antibiotics to efficiently
inhibit biofilm formation as well as diminish established biofilms
in A. pleuropneumoniae.
DISCUSSION
The bacterial TolC protein is multi-functional, and the most
distinguished role is to function as part of multidrug eﬄux system
that contributes to bacterial MDR (Zgurskaya et al., 2011). In
TABLE 3 | Susceptibility of A. pleuropneumoniae strains to different antimicrobials.
Drugs Test indexb (µg/ml) Strains
SC1516 tolC1::cat tolC1::cat tolC1+ SC1516+PAβN
Gentamicin MIC-P 4 4 4 4
MBC-B 40 10 40 20
Kanamycin MIC-P 16 8 >32a 16
MBC-B 160 160 / /
Rifampin MIC-P 0.5 0.5 0.5 0.015625
MBC-B 8 2 8 2
Ceftazidime MIC-P 1 0.125 1 0.5
MBC-B 16 4 8 2
Novobiocin MIC-P 16 0.0625 16 0.0625
MBC-B 32 0.125 16 4
Ciprofloxacin MIC-P 0.125 0.0625 0.125 0.125
MBC-B 2 2 2 /
Naldixic acid MIC-P 128 64 128 64
MBC-B 320 80 320 160
Ofloxacin MIC-P 0.25 0.125 0.25 0.125
MBC-B 4 1 4 2
Enrofloxacin MIC-P 0.25 0.0625 0.25 0.25
MBC-B 2 2 2 /
Vancomycin MIC-P 64 64 64 64
MBC-B 640 640 640 640
Lincomycin MIC-P 128 32 32 32
MBC-B 160 40 80 /
Tetracycline MIC-P 8 4 8 4
MBC-B 32 16 32 /
Polymyxin B MIC-P 2 2 2 1
MBC-B 16 16 16 /
Deoxycholate MIC-P >400 100 >400 <100
MBC-B / / / /
Acriflavine MIC-P 1 0.125 1 0.5
MBC-B 4 2 4 /
Crystal violet MIC-P 8 1 4 1
MBC-B 32 2 16 /
SDS MIC-P 128 32 128 16
MBC-B 160 40 160 /
PAβN MIC-P 80 10 80 /
MBC-B 320 80 160 /
aThe plasmids used in the complemented strains confer resistance to kanamycin. bMIC-P, minimal inhibitory concentration for planktonic cells; MBC-B, the minimal
bactericidal concentration for biofilms.
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FIGURE 4 | The loss of TolC1 or the addition of PAβN impaired biofilm formation in A. pleuropneumoniae. (A) The tolC1::cat had significantly reduced
ability to form biofilms. (B) PAβN inhibited biofilm formation of wild-type strain SC1516 in a dose-dependent manner. Data indicate the mean of three independent
experiments performed in duplicates and error bars show SDs. Asterisks indicate statistical significance using one-way ANOVA (∗P < 0.05).
FIGURE 5 | Inhibition of biofilm formation of A. pleuropneumoniae by antibiotics with or without the EPI PAβN. Biofilm formation of the WT strain SC1516
was significantly inhibited by subinhibitory concentrations of antibiotics (0.25 µg/ml of ceftazidime, 0.0625 µg/ml of ofloxacin or 1 µg/ml of gentamicin) in
combination with PAβN (60 µg/ml). Asterisks indicate statistical significance using two-way ANOVA (∗P < 0.05).
this study, we show that A. pleuropneumoniae encodes TolC1
and TolC2, which are highly conserved among all serotypes
of A. pleuropneumoniae. The presence of multiple TolC family
proteins is common in Gram-negative bacteria (Gil et al., 2006;
Kamal and Shafer, 2010). Generally, inactivation of any one of
those TolC-like proteins would alter antimicrobial susceptibility
to some extent (van Amsterdam et al., 2005; Lee et al., 2014).
Interestingly, our study demonstrates that only TolC1 forms a
part of the MDR machinery of A. pleuropneumoniae (Table 3;
Supplementary Table S2), even though both TolC1 and TolC2
are phylogenetically clustered as members of the multidrug eﬄux
group (Figure 1). In our work, we tried to construct a double
mutant and after many attempts, we failed due to an unsolved
reason. The actual role of TolC2 needs further study. A recent
study speculated that TolC2 may function in conjunction with
the MacAB-like proteins to mediate the biofilm dispersal in
A. pleuropneumoniae (Tremblay et al., 2013).
So, which proteins encoded by the A. pleuropneumoniae
genome could provide additional components for multidrug
eﬄux in association with TolC1 to pump antibacterial
compounds? Till now, no eﬄux pump has been characterized
in A. pleuropneumoniae yet. Genome analysis of the serotype
5b reference strain in GenBank predicts five multidrug eﬄux
pumps: an RND pump encoded by APL_0587 (acrB); an ABC
family transporter encoded by APL_0626 (macB); a MATE family
eﬄux transporter encoded by APL_0369 (norM); a SMR-type
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FIGURE 6 | Eradication of established biofilms of A. pleuropneumoniae by antibiotics with or without PAβN. (A) Biofilm eradication was significantly
increased by sub-bactericidal concentrations of antibiotics (1 µg/ml of ceftazidime, 1 µg/ml of ofloxacin, or 10 µg/ml of gentamicin) in combination with PAβN
(160 µg/ml). Data indicate mean of three independent experiments performed in duplicates, error bars indicate SD, ∗P < 0.05 when compared to the untreated
control using two-way ANOVA. CLSM images of persistent biofilm cells with intact cell membranes were colored green by SYTO 9 (B) and the biofilm matrix was
characterized by staining PGA with WGA-Oregon green (C). Overnight grown biofilms of A. pleuropneumoniae SC1516 were significantly eradicated by gentamicin
combining PAβN, showing sparse bacteria colonies and scattered WGA fluorescent spots.
transporter encoded by APL_1607 (emrE) and a major facilitator
superfamily pump encoded by APL_0355 (bcr). Additional
studied pumps include the membrane fusion protein AcrA
encoded by APL_0586 and the MacA homolog by APL_1814.
Among them, AcrAB would most likely to work with TolC1,
allowing for the eﬄux of a broad range of toxic compounds, as
revealed in other pathogens (Li and Nikaido, 2009).
To date, most published studies on TolC-dependent eﬄux
pumps have focused its function on MDR for planktonic cells,
with little known for biofilm cells (Anes et al., 2015). Biofilm-
dwelling bacteria are well-known to be more tolerant to the
antimicrobials than planktonic cells. However, the resistance
mechanisms are still not fully understood. Biofilm cells of
the tolC1 mutant strain showed significantly increased drug
susceptibility when compared to that of the parental strain,
indicating that TolC1 forms part of the multidrug eﬄux
machinery of A. pleuropneumoniae that mediate intrinsic MDR
of both planktonic and biofilm cells.
Unexpectedly, biofilm cells of the tolC1::cat mutant were more
susceptible to gentamicin and rifampin than that of the parental
strain, which showed no change in MIC-P assays (Table 3). It
is possible that changes in the composition of biofilm matrix of
tolC1::cat mutant caused the increased sensitivity to gentamicin
and rifampin (Mah, 2012). Additionally, inactivation of TolC1
was confirmed to impair biofilm formation. Therefore, the ability
to form competent biofilms appears to be another important
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function of TolC1 in contribution to MDR of biofilm cells of
A. pleuropneumoniae.
Bacterial eﬄux pumps, especially the clinically relevant
AcrAB-TolC, are often considered as important targets for
developing novel antibacterial treatments (Blair et al., 2014).
Consequently, EPIs, especially those against RND-type pumps,
attracted a lot of attention as potential adjunctive therapies
that would improve the potency of antibiotics and decrease
the emergence of MDR bacteria (Opperman and Nguyen,
2015). The EPI PAβN is known as a competitive inhibitor of
RND eﬄux pumps (Kinana et al., 2016). In this study, the
increased susceptibility of tolC1::cat to PAβN suggested a role
for TolC1 in PAβN eﬄux. Given the predicted eﬄux pumps in
A. pleuropneumoniae, PAβN is most likely to target AcrB and
competitively inhibit AcrAB-TolC system. Our results showed
that PAβN inhibited the eﬄux pumps of A. pleuropneumoniae
in a dose-dependent manner, with 60 µg/ml the most effective
against planktonic bacteria and 160 µg/ml against the biofilm
cells. Significantly, this concentration contrasted with that in a
previous study, in which 20 µg/ml of PAβN was sufficient to
increase drug susceptibility from 77 to 96% for E. coli MG1655
(Sáenz et al., 2004). This discrepancy suggested that the effects
of PAβN may vary to different bacterial species (Lister et al.,
2012).
PAβN has been used as a classical EPI of RND pumps, but
due to the dicationic character, its membrane-permeabilizing
effect, especially when used at high concentrations, has frequently
been ignored (Li et al., 2015). The OM-permeabilizing effect
could also increase antibiotic susceptibility, which is likely to
interfere with the judgment of PAβN on eﬄux pump inhibition.
In this study, when combined with 60 µg/ml PAβN in MIC-
P assays, the MIC of vancomycin—an antibiotic that is unable
to cross the outer membrane of Gram-negative bacteria—was
not changed (Table 3). These data suggested that 60 µg/ml of
PAβN seemed not to cause substantial outer membrane damage
of A. pleuropneumoniae. When 160 µg/ml of PAβN was used
in biofilm cells, the susceptibility to vancomycin was also not
changed with or without PAβN (Table 3). Besides, the effect of
PAβN on drug susceptibility of biofilm cells were also determined
in the presence of 1 mM MgSO4 to stabilize the outer membrane,
as described previously (Lamers et al., 2013). As a result, the
supplementation with magnesium did not restore the resistance
to gentamicin, rifampin, ceftazidime, novobiocin, nalidixic acid,
ofloxacin (data not shown), indicating that the ability of PAβN to
increase the drug susceptibility of biofilm cells seemed not due to
its permeabilizing activity.
Bacteria are capable of establishing biofilms on almost any
surfaces. Therefore, prevention of biofilm formation is the key in
thwarting biofilm-related infections. In clinics, bacteria are often
exposed to low concentration of antibiotics at the beginning and
end of a drug regimen, or continuously during low-dose therapy
(Kaplan, 2011). Several studies, including ours, have shown that
low doses of some antimicrobials induce biofilm formation in
a variety of bacterial species (Figure 5; Hoffman et al., 2005;
Kaplan et al., 2012). Importantly, our results indicate that PAβN
not only effectively suppresses the induction of biofilm formation
by low doses of antibiotics, but also significantly enhances the
therapeutic potential of low doses of antibiotics in inhibiting
biofilm formation of A. pleuropneumoniae.
Bacterial cells within established biofilms are highly resistant
to external antimicrobial agents (Mah, 2012). Because eﬄux
pumps confer many types of bacterial drug resistance (Blair et al.,
2014), not surprisingly, interference with the eﬄux pump activity
of biofilm cells restores the antibiotic sensitivity of biofilms.
Therefore, cocktail drugs composed of EPI with antibiotics are
projected to have greater potential of destroying established
biofilms. Indeed, PAβN significantly increases the ability of sub-
bactericidal concentration of antibiotics to eradicate established
biofilms of A. pleuropneumoniae. The demonstration that
PAβN suppresses biofilm formation whilst also potentiates the
eradication of established biofilms implies important therapeutic
value of the EPI.
CONCLUSION
We have characterized two TolC-like proteins, TolC1 and
TolC2, and only TolC1 function as a component of the
MDR machinery of A. pleuropneumoniae. TolC1-dependent
eﬄux pump(s) contributed to drug resistance of cells in
planktonic culture as well as in biofilms. Moreover, we
demonstrated a biofilm defect for the mutant lacking TolC1,
which facilitating an important role of TolC1 in biofilm
formation of A. pleuropneumoniae. Chemical inhibiting eﬄux
pumps by PAβN improved the efficacy of antibiotics as well as
repressed biofilm formation of A. pleuropneumoniae. In addition,
cocktail drugs composed of EPI with low concentration of
antibiotics, showed great potential to eradicate biofilms, which is
important in treating chronic infectious diseases. These findings
may contribute to understanding the molecular basis of MDR of
A. pleuropneumoniae, especially for the drug-tolerance biofilm
cells, and representing a step in controlling MDR and biofilm-
related infections in A. pleuropneumoniae.
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